Comparative Pharmacology
Head-to-head clinical analysis: GRISEOFULVIN ULTRAMICROSIZE versus ORAVIG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISEOFULVIN ULTRAMICROSIZE versus ORAVIG.
GRISEOFULVIN, ULTRAMICROSIZE vs ORAVIG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to tubulin, disrupting microtubule function and inhibiting fungal cell mitosis; deposited in keratin precursor cells, making keratin resistant to fungal invasion.
Miconazole, an azole antifungal, inhibits fungal cytochrome P450 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
250-375 mg orally once daily or 500-750 mg orally once daily for severe infections.
ORAVIG (miconazole) 50 mg buccal tablet applied once daily to the upper gum region (canine fossa) for 14 consecutive days. The tablet is placed with the rounded side against the gum and held in place for 30 seconds to ensure adhesion.
None Documented
None Documented
9-24 hours (mean 15 hours); prolonged in liver disease.
Terminal elimination half-life is approximately 24 hours, supporting once-daily buccal administration for sustained local oropharyngeal concentrations.
Renal (<1% unchanged); fecal (36% as metabolites); tissue deposition may persist for weeks.
Primarily fecal (approximately 52%) with 39% of the dose recovered in urine; less than 0.5% of the dose is excreted unchanged in urine.
Category D/X
Category C
Antifungal
Antifungal